2Champlin RE, Goldman JM, Gale RP, et al. Bone marrow transplantation in chronic myelogenous leukemia [ J ]. Semin in Hematol, 1988:25:74.
3Jerald. HLA-matched related HSCT for CP CML using a targeted BU and Cy preparative regimen[J]. Blood,2003,102:31 -35.
4Cliff RA,Buckner CD,Thornas ED, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia[ J]. Blood, 1994,84:4368 - 4373.
5Weisser M,Ledderose G,Kolb HJ,et al. Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over last decade [ J ]. Ann Hematol,2007,86 : 127 - 132.
6Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006 :transplant activity, long-term data and current result [ J ]. Haematologica,2006,91:513 - 521.
7McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia:a 9-year experience of the national marrow donor program [ J ]. Blood, 2000,95 (7) :2219 -2225.
8X-J Huang, D-H Liu, K-Y Liu, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies [ J ]. Bone Marrow Transplant,2006,38:291 -297.
10Daopei L, Lujia D, Tong W, et al. Conditioning including antithymocyte globulin followed by un-manipulated HLA-mismatched/ haploidentical HSCT can achieve comparable outcomes to HLA-identical sibling transplantation [ J ]. Blood, 2006, 107 ( 8 ) : 3065 - 3073.
二级参考文献12
1Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med, 1993, 328: 593-602.
2Beatty PG. Marrow transplantation using volunteer unrelated donors in a comparison of mismatched family donor transplants:a Seattle perspective. Bone Marrow Transplant, 1994, 14 Suppl 4: S39-41.
3Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med,1998, 339: 1186-1193.
4Mineishi S, Longo WL, Atkinson ME, et al. Addition of highdose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant, 1999, 23: 1217-1222.
5Hassan HT,Stockschlader M,Schleimer B,et al. Comparison of the content and subpopulation of CD3 and CD34 positive cells in bone marrow harvest and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transplant Immunol, 1996,
6Mielcarek M, Roecklein BA, Torok-Storb B. CD14+- cells in GCSF mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood,1996, 87: 574-580.
7Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte-colony stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood, 1995,86 :
8Arpinati M, Loken M, Anasetti C. G-CSF mobilizes type 2-derdritic cells rather than type 1-dendritic cells. Blood, 1998, 92Suppl 1: 111a.
9Ji SQ, Chen HR, Wang HX, et al. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Tran
10Ji SQ, Chen HR, Xun CQ, et al. The effect of G-CSF stimulated donor marrow on engraftment and incidence of graft-versushost disease in allogeneic bone marrow transplantation. Clin Transplant, 2001, 15: 317-323.
